Home / Intelligence / Case Studies / Early P&MA Forecasting Support for a Pipeline Asset
Trinity provided early P&MA forecasting support for a pipeline asset in development for several inflammatory conditions via secondary research.
Geographic Scope: 
Client Situation
The client wanted to uncover the optimal launch strategy for their pipeline asset by understanding the current and future landscape across several inflammatory diseases to support indication prioritization.
Trinity’s Solution
Trinity conducted secondary research into the clinical treatment algorithms and current pricing and market access (P&MA) landscape of 19 inflammatory diseases to understand the unmet need, level of competition, payer management, contracting and pricing benchmarks.
Trinity then ran a pipeline assessment to predict shifts within the landscape and evolution in P&MA benchmarks, and synthesized findings to deliver a comprehensive indication-by-indication achievable net pricing strategy for early P&MA forecasting inputs.
Deliverables
- Detailed XLS outlining current pricing and access status of competitor therapies including level of contracting and payer mix
- Pipeline analysis including likely price comparator, achievable net price and likely level of payer management
Project Outcomes & Impact
The key P&MA data that Trinity provided to inform inputs for the early P&MA forecast of the client’s pipeline asset enabled them to prioritize their development activities and launch strategy to optimize the commercial opportunity.
Related Intelligence
White Papers
Predicting Winners: AI-Powered Portfolio Management
Can artificial intelligence and machine learning (AIML) be used to support portfolio decision-making across the life sciences industry? In this installment of our Industry Impact Series, we find that not only can the latest AIML techniques identify the drivers of success and failure in commercialization, but Trinity Life Sciences’ AI algorithm accurately predicts revenue outcomes for […]
Read More
Webinars
Health Equity in HTA Outcomes: Navigating the New Frontier
April 30, 2025 | 11:00 – 11:45 AM ET / 17:00 – 17:45 CET
Join Value, Access and Pricing experts as they delve into the emerging role of health equity considerations as a differentiator in value narratives for global HTA (Health Technology Assessment) submissions. NICE’s proposed methods update focused on manufacturer-submitted evidence on health inequalities.
Sign Up Now
Webinars
Launch & Learn: Trinity Launch Accelerator
Available On Demand
Today’s launch environment is fraught with greater complexity, lack of standardization and executional inefficiency. Join us for a virtual lunch and learn where experts share how Launch Accelerator enables teams to overcome launch barriers with a simple launch readiness and management process.
Watch Now